Metabolon Partners with China Kadoorie Biobank to Advance Precision Health
The landmark multiomics study will examine how lifestyle, environmental, socioeconomic, and genetic factors play a significant role in shaping common...
Clinical Trial
CLISEQ, 10X Genomics and Weizmann Institute to Investigate Single Cell Applications in Hematology Clinical Diagnostics
Worldwide clinical PERIBLOOD™ trial by the Weizmann Institute to evaluate single cell RNA sequencing from blood as a Non-Invasive Path...
CLISEQ, 10X Genomics and Weizmann Institute to Investigate Single Cell Applications in Hematology Clinical Diagnostics
Worldwide clinical PERIBLOOD™ trial by the Weizmann Institute to evaluate single cell RNA sequencing from blood as a Non-Invasive Path...
Patient Identification for Clinical Trials Through AI and Real-World Data, Upcoming Webinar Hosted by Xtalks
In this free webinar, gain insight into the benefits and challenges of utilizing electronic health record (EHR) data as a...
Patient Identification for Clinical Trials Through AI and Real-World Data, Upcoming Webinar Hosted by Xtalks
In this free webinar, gain insight into the benefits and challenges of utilizing electronic health record (EHR) data as a...
PhaseV Partners with Bioforum to Bring AI-Powered Design Optimization to Clinical Trial Sponsors Worldwide
Integration of PhaseV's Trial Optimizer with Bioforum's Biometric CRO Services Creates an End-to-End Solution for Smarter, Faster, and More Efficient...
PhaseV Partners with Bioforum to Bring AI-Powered Design Optimization to Clinical Trial Sponsors Worldwide
Integration of PhaseV's Trial Optimizer with Bioforum's Biometric CRO Services Creates an End-to-End Solution for Smarter, Faster, and More Efficient...
Improving Clinical Response Signaling in Rare Disease Studies with Targeted Endpoint Data Quality Programs, Upcoming Webinar Hosted by Xtalks
In this free webinar, gain insight into strategies to improve data quality monitoring in rare disease clinical trials, including eCOA form optimization,...
West African Leaders Commit to Advance Lassa Fever Vaccine for the Region
In an historic moment for regional solidarity and leadership, West African Ministers of Health pledge their joint commitment to advance...
NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025
SHELTON, CONNECTICUT / ACCESS Newswire / September 9, 2025 / NanoViricides, Inc. (NYSE American:NNVC ) (the "Company"), a clinical stage...
NKGen Biotech, Inc. Announces Completion of NKMax Co., Ltd. Acquisition; Gains Full Control of Global Manufacturing and Intellectual Property Assets
NKGen acquires controlling stake in NKMax, marking a pivotal moment in its transformation into a fully integrated, self-sustaining, cell therapy...
Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer
16.0 months median progression free survival (mPFS) with firmonertinib 240 mg by blinded independent central review (BICR) in first-line patientsConfirmed...
Enlivex Announces Issuance of New Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis
Nes-Ziona, Israel, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy...
Anavex Life Sciences Announces Oral Blarcamesine Cognitive Resilience Results Approximating Normal Aging in New Precision Medicine Clinical Data from Phase IIb/III Alzheimer’s Disease Trial
New clinical Precision Medicine population 48-week data demonstrates unprecedented cognitive stabilization in early Alzheimer’s disease Cognitive outcomes observed in the...
Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead
Phase 1 data for efarindodekin alfa (XTX301) demonstrate promising anti-tumor activity in patients with advanced solid tumors Achievement of milestone...
Libtayo® (cemiplimab) Plus Chemotherapy Results at Five Years Reinforce Significant and Durable Improvements in Survival Outcomes for Advanced Non-small Cell Lung Cancer
Late-breaking data from exploratory analyses at WCLC show Libtayo plus chemotherapy demonstrates a more than double five-year overall survival rate...
Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress
- Late Breaking Abstract to Present Additional Data from Aclaris’ Phase 2a Trial of ATI-2138 in Atopic Dermatitis- WAYNE, Pa.,...
Biosplice Therapeutics Announces First Patient Dosed in NCI-Sponsored Clinical Trial of Cirtuvivint in Acute Myeloid Leukemia and Myelodysplastic Syndromes
SAN DIEGO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering advancements in small...
Scenic Biotech Appoints Dr. Roland W. Bürli as CSO to Advance Pipeline of Modifier Therapies in Neuro- and Metabolic Diseases
Scenic Biotech taps Dr. Bürli as Chief Scientific Officer to lead development of innovative drug candidate pipeline fueled by the...
Tourmaline Bio Enters into Agreement to be Acquired by Novartis AG
– Novartis to acquire Tourmaline Bio for $48.00 per share in cash for a total equity value of approximately $1.4...